# Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

> **NCT02434328** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 1048 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Brolucizumab ophthalmic solution
- **DRUG:** Aflibercept ophthalmic solution

## Key facts

- **NCT ID:** NCT02434328
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-28
- **Primary completion:** 2017-04-05
- **Final completion:** 2018-03-08
- **Target enrollment:** 1048 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02434328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02434328, "Efficacy and Safety of RTH258 Versus Aflibercept - Study 2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02434328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*